Common variation in cytochrome P450 epoxygenase genes and the risk of incident nonfatal myocardial infarction and ischemic stroke

Objective The biologically active epoxyeicosatrienoic acids have protective vascular effects. CYP2J2, CYP2C8, and CYP2C9 are known to be a source of epoxyeicosatrienoic acids in cardiac tissues. We conducted a population-based, case–control study at Group Health to determine whether common genetic variation in the CYP2J2, CYP2C8, and CYP2C9 genes was associated with the risk of myocardial infarction and ischemic stroke. Methods We used publicly available single nucleotide polymorphism discovery data from a mixed race panel of 90 individuals to select 30 tag-single nucleotide polymorphisms that were genotyped in 856 myocardial infarction cases, 368 stroke cases and 2688 controls. We used logistic regression to estimate additive associations. To account for multiple testing, we report q values alongside findings with P<0.05. Results Variation in CYP2J2 was associated with myocardial infarction risk (P=0.027, q=0.081). Two intronic CYP2J2 tag-single nucleotide polymorphisms, rs10889160 and rs11572325 were associated with an increased risk of myocardial infarction (odds ratio: 1.24, 95% confidence interval: 1.07–1.43, P=0.004, q=0.090, and odds ratio: 1.27, 95% confidence interval: 1.08–1.51, P=0.006, q=0.090, respectively). No evidence of an association was found between variation in CYP2J2 and stroke and there was no association between variation in CYP2C8 or CYP2C9 and myocardial infarction or stroke. Conclusion Common variation in CYP2J2 is associated with the risk of myocardial infarction.

[1]  P. Beaune,et al.  Reverse transcriptase-PCR quantification of mRNA levels from cytochrome (CYP)1, CYP2 and CYP3 families in 22 different human tissues , 2007, Pharmacogenetics and genomics.

[2]  D. Couper,et al.  CYP2J2 and CYP2C8 polymorphisms and coronary heart disease risk: the Atherosclerosis Risk in Communities (ARIC) study , 2007, Pharmacogenetics and genomics.

[3]  J. Hirschhorn,et al.  Genetic model testing and statistical power in population‐based association studies of quantitative traits , 2007, Genetic epidemiology.

[4]  J. Goldstein,et al.  Detection of Human CYP2C8, CYP2C9, and CYP2J2 in Cardiovascular Tissues , 2007, Drug Metabolism and Disposition.

[5]  P. Bugert,et al.  The -50G>T polymorphism in the promoter of the CYP2J2 gene in coronary heart disease: the Ludwigshafen Risk and Cardiovascular Health study. , 2007, Clinical chemistry.

[6]  T. Lumley,et al.  Association of genetic variations with nonfatal venous thrombosis in postmenopausal women. , 2007, JAMA.

[7]  Hua-Lin Wu,et al.  Synergistic effect of cytochrome P450 epoxygenase CYP2J2*7 polymorphism with smoking on the onset of premature myocardial infarction. , 2006, Atherosclerosis.

[8]  Thomas Lumley,et al.  Simple estimates of haplotype relative risks in case‐control data , 2006, Genetic epidemiology.

[9]  R. Busse,et al.  Endothelium-derived epoxyeicosatrienoic acids and vascular function. , 2006, Hypertension.

[10]  Y. Benjamini,et al.  Quantitative Trait Loci Analysis Using the False Discovery Rate , 2005, Genetics.

[11]  Teruhiko Yoshida,et al.  FUNCTIONAL CHARACTERIZATION OF FIVE NOVEL CYP2C8 VARIANTS, G171S, R186X, R186G, K247R, AND K383N, FOUND IN A JAPANESE POPULATION , 2005, Drug Metabolism and Disposition.

[12]  Kwang-Hyeon Liu,et al.  Identification and functional characterization of novel CYP2J2 variants: G312R variant causes loss of enzyme catalytic activity , 2005, Pharmacogenetics and genomics.

[13]  Dana C Crawford,et al.  Definition and clinical importance of haplotypes. , 2005, Annual review of medicine.

[14]  J. Liao,et al.  Vascular protective effects of cytochrome p450 epoxygenase-derived eicosanoids. , 2005, Archives of biochemistry and biophysics.

[15]  K. Huber,et al.  CYP2C9*2 and CYP2C9*3 alleles confer a lower risk for myocardial infarction. , 2004, Clinical chemistry.

[16]  K. Lindpaintner,et al.  Risk of Coronary Artery Disease Associated With Polymorphism of the Cytochrome P450 Epoxygenase CYP2J2 , 2004, Circulation.

[17]  C. Carlson,et al.  Selecting a maximally informative set of single-nucleotide polymorphisms for association analyses using linkage disequilibrium. , 2004, American journal of human genetics.

[18]  U. de Faire,et al.  Allelic variants of cytochromes P450 2C modify the risk for acute myocardial infarction. , 2003, Pharmacogenetics.

[19]  Peter Donnelly,et al.  A comparison of bayesian methods for haplotype reconstruction from population genotype data. , 2003, American journal of human genetics.

[20]  Thomas Lumley,et al.  Diuretic therapy, the alpha-adducin gene variant, and the risk of myocardial infarction or stroke in persons with treated hypertension. , 2002, JAMA.

[21]  Alex P. Reiner,et al.  Diuretic Therapy, the α-Adducin Gene Variant, and the Risk of Myocardial Infarction or Stroke in Persons With Treated Hypertension , 2002 .

[22]  H. Mohrenweiser,et al.  Cloning of CYP2J2 gene and identification of functional polymorphisms. , 2002, Molecular pharmacology.

[23]  Yoshiro Saito,et al.  Five novel single nucleotide polymorphisms in the CYP2C8 gene, one of which induces a frame-shift. , 2002, Drug metabolism and pharmacokinetics.

[24]  C. Day,et al.  Candidate gene case-control association studies: advantages and potential pitfalls. , 2001, British journal of clinical pharmacology.

[25]  J. Goldstein,et al.  Polymorphisms in human CYP2C8 decrease metabolism of the anticancer drug paclitaxel and arachidonic acid. , 2001, Pharmacogenetics.

[26]  D. Zeldin.  Epoxygenase Pathways of Arachidonic Acid Metabolism* , 2001, The Journal of Biological Chemistry.

[27]  A. LaCroix,et al.  Hormone replacement therapy, prothrombotic mutations, and the risk of incident nonfatal myocardial infarction in postmenopausal women. , 2001, JAMA.

[28]  K. Ley,et al.  Anti-inflammatory properties of cytochrome P450 epoxygenase-derived eicosanoids. , 1999, Science.

[29]  M H Tarbit,et al.  Genetic analysis of the human cytochrome P450 CYP2C9 locus. , 1996, Pharmacogenetics.

[30]  K. Tomer,et al.  Molecular Cloning and Expression of CYP2J2, a Human Cytochrome P450 Arachidonic Acid Epoxygenase Highly Expressed in Heart (*) , 1996, The Journal of Biological Chemistry.

[31]  T. Raghunathan,et al.  The risk of myocardial infarction associated with antihypertensive drug therapies. , 1995, JAMA.

[32]  L H Kuller,et al.  Surveillance and ascertainment of cardiovascular events. The Cardiovascular Health Study. , 1995, Annals of epidemiology.

[33]  Y. Benjamini,et al.  Controlling the false discovery rate: a practical and powerful approach to multiple testing , 1995 .

[34]  N. Pearce,et al.  What does the odds ratio estimate in a case-control study? , 1993, International journal of epidemiology.

[35]  J. Gardin,et al.  Assessment of cerebrovascular disease in the Cardiovascular Health Study. , 1993, Annals of epidemiology.

[36]  Shirley A. Miller,et al.  A simple salting out procedure for extracting DNA from human nucleated cells. , 1988, Nucleic acids research.